Sanofi

CIK 0001121404 · Q2 2026

13F Equity AUM

$534.0M

+59.0% QoQ

Positions

+1 QoQ

AUM Rank

#3,537

Top 40%

Skill Alpha (FF)

—

Building track record (6q)

Quarters Tracked

~1 years

Portfolio Concentration

Top 5: 80.9%Top 10: 100.0%Top 20: 100.0%

MGTX30.9%

INBX20.5%

NVV112.1%

ANAB10.4%

Odyssey Therapeutics Inc.7.0%

Agomab Therapeutics NV6.8%

MPLT6.1%

First Tracks Biotherapeutics Inc.3.1%

IMRX2.5%

QTTB0.6%

HHI (Herfindahl-Hirschman Index) measures portfolio concentration. Low (<1500) = diversified, Moderate (1500-2500), High (>2500) = concentrated bets.

Sector Allocation

Healthcare83.2%

Unclassified16.8%

Portfolio weight by GICS sector based on latest 13F filing. Sectors below 2% are grouped as “Other.”

Position Sizing

Positions: 10Median: 6.87%Avg: 10.00%

0–0.5%

0(0.0%)

0.5–1%

1(0.6%)

1–3%

1(2.5%)

3–5%

1(3.1%)

5%+

7(93.8%)

Count of positions per weight bucket — (%) = combined portfolio weight

Loading summary cards...

Portfolio Overlap

Shared: 0Unique: 10vs 20 funds

0%Low

Fund positions

Consensus CUSIPs

Jaccard similarity of this fund’s portfolio vs the consensus of top 20 funds by AUM. Low (<15%) = contrarian, Moderate (15-40%), High (>40%) = follows the crowd.

Loading overlap analysis...

Position Changes This Quarter

New2Increased0Decreased0Exited1

New Positions

Odyssey Therapeutics…7.0%

+2.0M

First Tracks Biother…3.1%

+822K

Exited

ELDN

-814,980

Quarter-over-quarter changes compared to prior 13F filing. New = first appearance; Exited = no longer held.

Loading position changes...

Holdings

Loading holdings...